Evaluation of the Public Health Interest of Kaletra: Impact on Resistance to ARVs - EOLE.
Phase of Trial: Phase III
Latest Information Update: 24 Jun 2014
At a glance
- Drugs Lopinavir/ritonavir (Primary)
- Indications HIV infections
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms EOLE
- Sponsors Abbott Laboratories
- 13 Dec 2011 Actual end date (Jul 2009) added as reported by ClinicalTrials.gov.
- 13 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 May 2011 Actual initiation date changed from Dec 2007 to Mar 2008 as reported by ClinicalTrials.gov.